Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–70.

Article  PubMed  Google Scholar 

Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729–35.

Article  PubMed  Google Scholar 

Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol. 2021;35:101692.

Article  PubMed  Google Scholar 

Helliwell P, Coates L, Chandran V, et al. Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res. 2014;66:1759–66.

Article  Google Scholar 

Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83:706–19.

Article  CAS  PubMed  Google Scholar 

Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71:2–29.

Article  PubMed  Google Scholar 

Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465–79.

Article  PubMed  PubMed Central  Google Scholar 

Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71:1112–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vieira-Sousa E, Alves P, Rodrigues AM, et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann Rheum Dis. 2020;79:490–8.

Article  CAS  PubMed  Google Scholar 

U.S. Food and Drug Administration. Xeljanz® (tofacitinib): highlights of prescribing information. 2024. https://labeling.pfizer.com/showlabeling.aspx?id=959. Accessed Jan 23, 2025.

Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–50.

Article  CAS  PubMed  Google Scholar 

Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525–36.

Article  CAS  PubMed  Google Scholar 

Leng X, Lin W, Liu S, et al. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2023;9:e002559.

Article  PubMed  PubMed Central  Google Scholar 

Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL balance long-term extension study. Lancet Rheumatol. 2021;3:e270–83.

Article  CAS  PubMed  Google Scholar 

Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7:e001595.

Article  PubMed  PubMed Central  Google Scholar 

Nash P, Mease PJ, Fleishaker D, et al. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL balance. Lancet Rheumatol. 2021;3:e28–39.

Article  CAS  PubMed  Google Scholar 

Koehm M, Rossmanith T, Foldenauer AC, et al. Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial. Lancet Rheumatol. 2023;5:e14–23.

Article  CAS  PubMed  Google Scholar 

Combe B, Behrens F, McHugh N, et al. Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials. J Rheumatol. 2016;43:1063–7.

Article  CAS  PubMed  Google Scholar 

Strand V, Mease PJ, Maksabedian Hernandez EJ, et al. Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. RMD Open. 2021;7:e001484.

Article  PubMed  PubMed Central  Google Scholar 

Mease PJ, Young P, Fallon L, et al. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2024;11:313–29.

Article  PubMed  PubMed Central  Google Scholar 

Tokareva K, Reid P, Yang V, et al. JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023;19:1385–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolfe F, Butler SH, Fitzcharles M, et al. Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria. Scand J Pain. 2019;20:77–86.

Article  PubMed  Google Scholar 

Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open. 2019;5:e000880.

Article  PubMed  PubMed Central  Google Scholar 

Ogdie A, O’Brien J, Malley W, et al. Effectiveness by disease severity in patients with psoriatic arthritis treated with apremilast in the CorEvitas psoriatic arthritis/spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol. 2022;74(Suppl 9).

Mease PJ, Papademetriou E, Potluri R, Agarwal E, Cappelleri JC, Ling YL. Adherence, persistence, healthcare resource use, and costs in tofacitinib-treated patients with psoriatic arthritis: data from two United States claims databases. Adv Ther. 2024;41:3850–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lorenzin M, Ortolan A, Cozzi G, et al. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clin Rheumatol. 2021;40:4569–80.

Article  PubMed  PubMed Central  Google Scholar 

Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs RD. 2017;17:509–22.

Article  CAS  Google Scholar 

Xie Y, Liu Y, Liu Y. Are biologics combined with methotrexate better than biologics monotherapy in psoriasis and psoriatic arthritis: a meta-analysis of randomized controlled trials. Dermatol Ther. 2021;34:e14926.

Article  CAS  PubMed  Google Scholar 

Mease PJ, Reddy S, Ross S, et al. Evaluating the efficacy of biologics with and without methotrexate in the treatment of psoriatic arthritis: a network meta-analysis. RMD Open. 2024;10:e003423.

Article  PubMed  PubMed Central  Google Scholar 

Thomas ML, Shaddick G, Charlton R, et al. Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases. J Rheumatol. 2021;48:48–57.

Article  PubMed  Google Scholar 

Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;1:e000181.

Article  PubMed  PubMed Central  Google Scholar 

Mease PJ, Ogdie A, Tesser J, et al. Improvements in patient-reported outcomes through six months of guselkumab treatment in patients with active psoriatic arthritis: real-world data from the CorEvitas psoriatic arthritis/spondyloarthritis registry. ACR Open Rheumatol. 2024;6:304–11.

Article  PubMed  PubMed Central  Google Scholar 

Karadag O, Dalkilic E, Ayan G, et al. Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis und